中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(9): 1778-1784

Clinical features of primary biliary cholangitis patients with negative or positive anti-mitochondrial antibody： A comparative study

DOI: 10.12449/JCH240910
  • 1.

    Department of Integrative Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

  • 2.

    Department of Comprehensive Internal Medicine，Chifeng Traditional Chinese Medicine and Mongolian Medicine Hospital，Chifeng，Inner Mongolia 024000，China

Research funding:

National Administration of Traditional Chinese Medicine High Level Key Discipline Construction Project of Traditional Chinese Medicine (zyyzdxk-2023005)

More Information
  • Corresponding author: ZHOU Guiqin， zhouguiqin@ccmu.edu.cn （ORCID： 0000-0002-1035-0181）
  • Received Date: 2023-12-10
  • Accepted Date: 2024-01-29
  • Published Date: 2024-09-25
    Abstract
  •   Objective  To investigate the differences in clinical features between the primary biliary cholangitis （PBC） patients with negative or positive anti-mitochondrial antibody （AMA） by analyzing related immune and biochemical parameters.  Methods  This study was conducted among the patients who attended Beijing Ditan Hospital， Capital Medical University， from January 2013 to December 2022 and were diagnosed with PBC， and they were divided into AMA negative group with 139 patients （24.5%） and AMA positive group with 428 patients （75.5%）. Propensity score matching at a ratio of 1∶1 was performed with age and sex as matching factors and a matching tolerance of 0.06. Liver function， coagulation， and immune parameters on admission were analyzed， as well as the changes in liver function and other indicators after 6 months of treatment and the response to ursodeoxycholic acid （UDCA） at 6 and 12 months of treatment. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups.  Results  There were 139 AMA-negative PBC patients and 139 AMA-positive PBC patients after propensity score matching. Compared with the AMA positive group on admission， the AMA negative group had significantly lower levels of direct bilirubin and globulin （Glo） and significantly higher levels of albumin， albumin/globulin ratio， prealbumin， and fibrinogen （all P<0.05）. After 6 months of UDCA treatment， there were significant differences in Glo and prealbumin between the AMA negative group and the AMA positive group （P<0.05）. Both the AMA negative group and the AMA positive group had an increase in prealbumin after 6 months of treatment， and the AMA negative group had a significantly greater increase than the AMA positive group （U=41.00， P=0.015）. After UDCA treatment for 6 and 12 months， there was no significant difference in treatment response to UDCA between the AMA negative group and the AMA positive group （all P>0.05）.  Conclusion  After matching for age and sex， compared with the AMA-positive PBC patients， the AMA-negative PBC patients tend to have a milder degree of liver inflammation and damage， significantly greater improvements in inflammation and liver synthesis ability after UDCA treatment， and better response to UDCA.

     

    • FullText(HTML)
    • References(26)
  • [1]
    NGUYEN DL, JURAN BD, LAZARIDIS KN. Primary biliary cirrhosis[J]. Best Pract Res Clin Gastroenterol, 2010, 24( 5): 647- 654. DOI: 10.1016/j.bpg.2010.07.006.
    [2]
    TANAKA A, LEUNG PS, GERSHWIN ME. Environmental basis of primary biliary cholangitis[J]. Exp Biol Med(Maywood), 2018, 243( 2): 184- 189. DOI: 10.1177/1535370217748893.
    [3]
    CHENG TC, LIU YC, XUE H, et al. Clinical manifestations and biochemical indexes of patients with primary biliary cholangitis with negative anti-mitochondria antibody M2 subtype[J]. J Nantong Univ Med Sci, 2022, 42( 6): 508- 512. DOI: 10.16424/j.cnki.cn32-1807/r.2022.06.003.

    程苕莼, 刘一村, 薛红, 等. 抗线粒体抗体M2亚型阴性原发性胆汁性胆管炎的临床表现与生化指标分析[J]. 南通大学学报(医学版), 2022, 42( 6): 508- 512. DOI: 10.16424/j.cnki.cn32-1807/r.2022.06.003.
    [4]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2018, 69( 1): 394- 419. DOI: 10.1002/hep.30145.
    [5]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 35- 41. http://dx.doi.org/10.3969/j.issn.1001-5256.2022.01.007. DOI: 10.3969/j.issn.1001-5256.2022.01.007

    中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 35- 41. http://dx.doi.org/10.3969/j.issn.1001-5256.2022.01.007. DOI: 10.3969/j.issn.1001-5256.2022.01.007
    [6]
    CHEN HH, YOU DF, JIU L, et al. Comparison and application of matching in propensity score method and mahalanobis distance method[J]. Chin J Health Stat, 2017, 34( 6): 857- 860, 865.

    陈会会, 尤东方, 酒励, 等. 倾向性评分法和马氏距离法在匹配中的比较与应用[J]. 中国卫生统计, 2017, 34( 6): 857- 860, 865.
    [7]
    ZHANG FK, JIA JD, WANG BE, et al. Clinical characteristics of primary biliary cirrhosis: A report of 45 cases[J]. Chin J Intern Med, 2002, 41( 3): 163- 167.

    张福奎, 贾继东, 王宝恩, 等. 45例原发性胆汁性肝硬化的临床特征[J]. 中华内科杂志, 2002, 41( 3): 163- 167.
    [8]
    DONALDSON P, AGARWAL K, CRAGGS A, et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: Associations with disease progression and disease susceptibility[J]. Gut, 2001, 48( 3): 397- 402. DOI: 10.1136/gut.48.3.397.
    [9]
    LI CP, HWANG SJ, CHAN CY, et al. Clinical evaluation of primary biliary cirrhosis in Chinese patients without serum anti-mitochondrial antibody[J]. Zhonghua Yi Xue Za Zhi(Taipei), 1997, 59( 6): 334- 340.
    [10]
    LIU HL. Comparison of clinical and pathological characteristics between negative and positive anti-mitochondrial antibodies in patients with primary biliary cholangitis[D]. Nanjing: Southeast University, 2019.

    刘红丽. 抗线粒体抗体阴性和阳性的原发性胆汁性胆管炎患者临床及病理特征比较[D]. 南京: 东南大学, 2019.
    [11]
    TANAKA A, LEUNG PSC, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195( 1): 25- 34. DOI: 10.1111/cei.13198.
    [12]
    FANG JY, ZHU ZP, LI K, et al. Study on the expression of PDC-E2 antibody in autoimmune liver diseases[J]. Chin Hepatol, 2017, 22( 1): 34- 37. DOI: 10.14000/j.cnki.issn.1008-1704.2017.01.012.

    方静怡, 朱正鹏, 李凯, 等. PDC-E2抗体在自身免疫性肝病的表达研究[J]. 肝脏, 2017, 22( 1): 34- 37. DOI: 10.14000/j.cnki.issn.1008-1704.2017.01.012.
    [13]
    LIU HY, ZHANG J, DENG AM, et al. Functional analysis of HLA-A*0201-restricted PDC-E2 specific CTLs in primary biliary cirrhosis[J]. Chin J Immunol, 2007, 23( 6): 555- 558.

    刘海英, 张建, 邓安梅, 等. 原发性胆汁性肝硬化HLA-A*0201限制性PDC-E2特异性CTL功能分析[J]. 中国免疫学杂志, 2007, 23( 6): 555- 558.
    [14]
    HUANG PJ, PAN ZF, SU HK. Prognostic vale of CRP/ALB ratio and NLR in cervical squamous cell carcinoma[J]. Transl Med J, 2019, 8( 2): 85- 88. DOI: 10.3969/j.issn.2095-3097.2019.02.005.

    黄培坚, 潘志锋, 苏鸿凯. 联合CRP/ALB比值和NLR对宫颈鳞状细胞癌预后的评估价值[J]. 转化医学杂志, 2019, 8( 2): 85- 88. DOI: 10.3969/j.issn.2095-3097.2019.02.005.
    [15]
    ZHOU HY, ZHOU CW. Research progress on serum globulin, cholinesterase and their ratios and evaluation of liver reserve function in liver cirrhosis[J]. Chin J Clin Gastroenterol, 2019, 31( 4): 267- 270. DOI: 10.3870/lcxh.j.issn.1005-541X.2019.04.20.

    周红宇, 周昌文. 血清球蛋白、胆碱酯酶及其比值与肝硬化肝脏储备功能评估的研究进展[J]. 临床消化病杂志, 2019, 31( 4): 267- 270. DOI: 10.3870/lcxh.j.issn.1005-541X.2019.04.20.
    [16]
    GONG YW. Interpretation of common liver function test indexes[J]. Sci Technol Fam, 2023, 5: 54- 55. DOI: 10.3969/j.issn.1005-7293.2023.05.025.

    龚彦文. 常见肝功能检验指标的解读[J]. 家庭科技, 2023, 5: 54- 55. DOI: 10.3969/j.issn.1005-7293.2023.05.025.
    [17]
    ZHOU JL, HUANG JQ, HE B, et al. A contrastive research of A/G ratio and anterior width of right branch of protal vein in the diagnosis of hepatic fibrosis[J]. Chin Gen Pract, 2017, 20( S2): 9- 12.

    周家龙, 黄建强, 何波, 等. 白球比、门脉右支前间隙对肝纤维化的诊断对比研究[J]. 中国全科医学, 2017, 20( S2): 9- 12.
    [18]
    LIAO YY, TENG CL, PENG NF, et al. Serum prealbumin is negatively associated with survival in hepatocellular carcinoma patients after hepatic resection[J]. J Cancer, 2019, 10( 13): 3006- 3011. DOI: 10.7150/jca.30903.
    [19]
    SONG SJ, SU GH. Application of serum total bile acid, cholinesterase and prealbumin detection in the diagnosis of liver disease[J]. J Med Inf, 2021, 34( 23): 9- 11. DOI: 10.3969/j.issn.1006-1959.2021.23.002.

    宋少娟, 苏国华. 血清总胆汁酸、胆碱酯酶和前白蛋白检测在肝病诊断中应用探析[J]. 医学信息, 2021, 34( 23): 9- 11. DOI: 10.3969/j.issn.1006-1959.2021.23.002.
    [20]
    HUANG F, GAO J. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy[J]. World J Gastroenterol, 2020, 26( 7): 749- 758. DOI: 10.3748/wjg.v26.i7.749.
    [21]
    WEI LY, ZHAI YZ, FENG GH. New advances in the use of serum prealbumin as an index of liver function[J]. World Chin J Dig, 2013, 21( 15): 1387- 1393.

    韦丽娅, 翟永贞, 冯国和. 血清前白蛋白对肝功能评估的研究进展[J]. 世界华人消化杂志, 2013, 21( 15): 1387- 1393.
    [22]
    COLLEN D, TYTGAT GN, CLAEYS H, et al. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans[J]. Br J Haematol, 1972, 22( 6): 681- 700. DOI: 10.1111/j.1365-2141.1972.tb05715.x.
    [23]
    XU CH, WU LF, CHEN H. Value analysis of prothrombin time combined with platelet parameters and fibrinogen detection in the diagnosis of liver cirrhosis[J]. Mod Diagn Treat, 2022, 33( 14): 2125- 2127, 2130.

    许才红, 吴路发, 陈华. 凝血酶原时间联合血小板参数及纤维蛋白原检测在肝硬化诊断中的价值分析[J]. 现代诊断与治疗, 2022, 33( 14): 2125- 2127, 2130.
    [24]
    HU X, CHENG C, FENG LM. Changes in the levels of D-dimer and CoagulationFactor in patients with liver cirrhosis[J]. J Mod Lab Med, 2013, 28( 2): 60- 62. DOI: 10.3969/j.issn.1671-7414.2013.02.017.

    胡晓, 程超, 冯立民. 乙型肝炎后肝硬化患者凝血功能和血浆D-二聚体水平与Child-Pugh肝功能分级的关系分析[J]. 现代检验医学杂志, 2013, 28( 2): 60- 62. DOI: 10.3969/j.issn.1671-7414.2013.02.017.
    [25]
    BUDNICK IM, DAVIS JPE, SUNDARARAGHAVAN A, et al. Transfusion with cryoprecipitate for very low fibrinogen levels does not affect bleeding or survival in critically ill cirrhosis patients[J]. Thromb Haemost, 2021, 121( 10): 1317- 1325. DOI: 10.1055/a-1355-3716.
    [26]
    PECHLIVANI N, KEARNEY KJ, AJJAN RA. Fibrinogen and antifibrinolytic proteins: Interactions and future therapeutics[J]. Int J Mol Sci, 2021, 22( 22): 12537. DOI: 10.3390/ijms222212537.
    • Relative Articles

  • Relative Articles

    [1]Chenlu ZHAO, Dongfang SHANG, Cheng ZHOU, Junhao SHI, Wenxia ZHAO. Mechanism of lipid metabolism mediated by hepatokines and adipokines in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(1): 168-174. doi: 10.3969/j.issn.1001-5256.2023.01.026
    [2]Hua ZHANG, Xuanxuan KOU, Jingxin DENG, Jiangang ZHANG. Regulatory role of hypoxia－inducible factor－1α/Yes－associated protein in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(9): 2191-2197. doi: 10.3969/j.issn.1001-5256.2023.09.024
    [3]Shuang ZHANG, Xiaohui LIU, Gang WANG, Li ZHANG, Yunjie ZHU, Jian WU, Yali LIU, Jing ZHANG. Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population[J]. Journal of Clinical Hepatology, 2022, 38(3): 547-552. doi: 10.3969/j.issn.1001-5256.2022.03.011
    [4]Tingting QIN, Ruihua ZHANG, Yu ZHANG, Xiaodong WEI, Xiaoyu WEN. Mechanism and treatment of polycystic ovary syndrome with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(3): 660-665. doi: 10.3969/j.issn.1001-5256.2022.03.035
    [5]Yanhua TANG, Xingyu LU, Jian SUN. Chronic hepatitis B virus infection with nonalcoholic fatty liver disease: Problems faced by antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1508-1514. doi: 10.3969/j.issn.1001-5256.2021.07.004
    [6]Qin LIU, Qiang ZHANG, Fangxiong WU, Rong YAN, Rong LI, Jia WANG, Chunyan NIU. Effect of amitriptyline on lipid deposition and biochemical metabolism in a cell model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(1): 99-104. doi: 10.3969/j.issn.1001-5256.2021.01.020
    [7]Dongxu WANG, Chuan XING, Bo LYU, Han ZHAO, Bing HE. Risk factors for polycystic ovary syndrome with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2474-2477. doi: 10.3969/j.issn.1001-5256.2021.10.046
    [8]Yuting LUAN, Zhongming HUANG, Wenjuan SHEN, Minghao HA, Zhibing XU. Research advances in metabolomics in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 943-946. doi: 10.3969/j.issn.1001-5256.2021.04.047
    [9]Xiajie WEN, Guixin LI, Jie LI, Huiying RAO, Jidong JIA, Fengmin LU. Interaction between hepatitis B virus replication and lipid metabolism in patients with chronic hepatitis B and NAFLD[J]. Journal of Clinical Hepatology, 2021, 37(7): 1495-1500. doi: 10.3969/j.issn.1001-5256.2021.07.002
    [10]Zhang YiZhi, Duan ZhongPing, Zhang XiaoHui, Chen Yu. Effect of Ganshuang granules on lipid metabolism in a new tissue-engineering model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(7): 1551-1555. doi: 10.3969/j.issn.1001-5256.2020.07.020
    [11]Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024
    [12]Zhang Yang, Li JunXiang, Wang YunLiang. Role of bile acid metabolism and related receptors in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1374-1377. doi: 10.3969/j.issn.1001-5256.2020.06.040
    [13]FENG Gong, YAN QinQin, HE Na, MI Man. From nonalcoholic fatty liver disease to metabolic fatty liver disease:An analysis based on disease heterogeneity[J]. Journal of Clinical Hepatology, 2020, 36(11): 2597-2600. doi: 10.3969/j.issn.1001-5256.2020.11.045
    [14]Gao JingJing, Wang Tao, Jiang YuanYe, Cao Qin. Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(8): 1880-1882. doi: 10.3969/j.issn.1001-5256.2020.08.044
    [15]Zhong Rui, Yan YongFeng, Jiang Xin, Xu Huan, Peng Yan, Wang Min, Fu WenGuang, Tang XiaoWei. Clinical features of acute pancreatitis with metabolic syndrome and influencing factors for prognosis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1794-1798. doi: 10.3969/j.issn.1001-5256.2020.08.023
    [16]LI XianQiu, LIU Hui, XIAO ChunTao, LUO Gang, ZHOU Xian. Influence of metabolic syndrome on patients with recurrence of hypertriglyceridemic acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2515-2520. doi: 10.3969/j.issn.1001-5256.2020.11.023
    [17]Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010
    [18]Lu Xu, Han Tao, Tian Yao, Lu BoWei, Zhang Qian. Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J]. Journal of Clinical Hepatology, 2014, 30(11): 1225-1228. doi: 10.3969/j.issn.1001-5256.2014.11.034
    [19]Niu ChunYan, Yan Rong, Tian Yu, Ma HuiXia, Jiao ShuJiang. The prevalence of fatty liver disease and its relationship with metabolic syndrome[J]. Journal of Clinical Hepatology, 2010, 26(2): 167-169.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 24.3 %FULLTEXT: 24.3 %META: 61.7 %META: 61.7 %PDF: 14.0 %PDF: 14.0 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.2 %其他: 6.2 %其他: 1.0 %其他: 1.0 %Central District: 0.2 %Central District: 0.2 %China: 0.1 %China: 0.1 %Konya: 0.1 %Konya: 0.1 %Richardson: 0.1 %Richardson: 0.1 %上海: 7.1 %上海: 7.1 %上饶: 0.2 %上饶: 0.2 %临汾: 0.2 %临汾: 0.2 %伊利诺伊州: 0.1 %伊利诺伊州: 0.1 %伊犁: 0.1 %伊犁: 0.1 %信阳: 0.3 %信阳: 0.3 %兰州: 0.1 %兰州: 0.1 %内江: 0.2 %内江: 0.2 %包头: 0.2 %包头: 0.2 %北京: 6.5 %北京: 6.5 %十堰: 0.1 %十堰: 0.1 %华盛顿州: 0.1 %华盛顿州: 0.1 %南京: 1.3 %南京: 1.3 %南宁: 0.3 %南宁: 0.3 %南平: 0.2 %南平: 0.2 %南昌: 0.2 %南昌: 0.2 %卡纳塔克: 0.1 %卡纳塔克: 0.1 %厦门: 0.3 %厦门: 0.3 %合肥: 0.2 %合肥: 0.2 %吉林: 0.7 %吉林: 0.7 %吉隆坡: 0.1 %吉隆坡: 0.1 %呼和浩特: 0.3 %呼和浩特: 0.3 %咸阳: 0.1 %咸阳: 0.1 %哈尔滨: 0.2 %哈尔滨: 0.2 %哥伦布: 0.1 %哥伦布: 0.1 %嘉兴: 0.1 %嘉兴: 0.1 %四平: 0.2 %四平: 0.2 %埃森: 0.2 %埃森: 0.2 %天津: 0.3 %天津: 0.3 %太原: 0.5 %太原: 0.5 %孝感: 0.6 %孝感: 0.6 %孟买: 0.2 %孟买: 0.2 %宁波: 0.2 %宁波: 0.2 %安康: 0.3 %安康: 0.3 %宣城: 0.5 %宣城: 0.5 %山景城: 0.2 %山景城: 0.2 %巴音郭楞: 0.2 %巴音郭楞: 0.2 %常州: 0.1 %常州: 0.1 %常德: 0.3 %常德: 0.3 %广安: 0.1 %广安: 0.1 %广州: 1.1 %广州: 1.1 %开封: 0.2 %开封: 0.2 %张家口: 1.0 %张家口: 1.0 %张家界: 0.2 %张家界: 0.2 %徐州: 0.2 %徐州: 0.2 %悉尼: 0.1 %悉尼: 0.1 %成都: 1.0 %成都: 1.0 %扬州: 0.2 %扬州: 0.2 %抚顺: 0.2 %抚顺: 0.2 %攀枝花: 0.1 %攀枝花: 0.1 %无锡: 0.3 %无锡: 0.3 %昆明: 3.0 %昆明: 3.0 %曲靖: 0.1 %曲靖: 0.1 %杭州: 2.3 %杭州: 2.3 %株洲: 0.2 %株洲: 0.2 %格兰特县: 0.1 %格兰特县: 0.1 %榆林: 0.2 %榆林: 0.2 %武汉: 1.2 %武汉: 1.2 %汕头: 0.2 %汕头: 0.2 %沈阳: 0.6 %沈阳: 0.6 %泉州: 0.1 %泉州: 0.1 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.1 %洛阳: 0.1 %济南: 0.8 %济南: 0.8 %济宁: 0.1 %济宁: 0.1 %海得拉巴: 0.5 %海得拉巴: 0.5 %淮安: 0.1 %淮安: 0.1 %深圳: 0.7 %深圳: 0.7 %温州: 0.1 %温州: 0.1 %湖州: 0.1 %湖州: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.3 %漯河: 0.3 %潍坊: 0.1 %潍坊: 0.1 %班加罗尔: 0.1 %班加罗尔: 0.1 %眉山: 0.3 %眉山: 0.3 %石家庄: 0.3 %石家庄: 0.3 %福州: 0.3 %福州: 0.3 %绍兴: 0.2 %绍兴: 0.2 %罗奥尔凯埃: 0.1 %罗奥尔凯埃: 0.1 %芒廷维尤: 27.9 %芒廷维尤: 27.9 %芝加哥: 2.0 %芝加哥: 2.0 %苏州: 0.5 %苏州: 0.5 %荆州: 0.1 %荆州: 0.1 %莫斯科: 0.9 %莫斯科: 0.9 %葫芦岛: 0.1 %葫芦岛: 0.1 %衡水: 0.1 %衡水: 0.1 %襄阳: 0.2 %襄阳: 0.2 %西宁: 6.4 %西宁: 6.4 %西安: 1.0 %西安: 1.0 %西雅图: 0.1 %西雅图: 0.1 %诺沃克: 0.8 %诺沃克: 0.8 %贵阳: 0.4 %贵阳: 0.4 %赣州: 0.1 %赣州: 0.1 %运城: 0.9 %运城: 0.9 %遵义: 0.1 %遵义: 0.1 %邯郸: 0.1 %邯郸: 0.1 %郑州: 0.4 %郑州: 0.4 %都柏林: 0.1 %都柏林: 0.1 %酒泉: 0.2 %酒泉: 0.2 %重庆: 0.8 %重庆: 0.8 %铜仁: 0.2 %铜仁: 0.2 %镇江: 0.2 %镇江: 0.2 %长春: 7.0 %长春: 7.0 %长沙: 1.2 %长沙: 1.2 %长治: 0.4 %长治: 0.4 %随州: 0.1 %随州: 0.1 %雷德蒙德: 0.1 %雷德蒙德: 0.1 %青岛: 0.4 %青岛: 0.4 %香港: 0.1 %香港: 0.1 %其他其他Central DistrictChinaKonyaRichardson上海上饶临汾伊利诺伊州伊犁信阳兰州内江包头北京十堰华盛顿州南京南宁南平南昌卡纳塔克厦门合肥吉林吉隆坡呼和浩特咸阳哈尔滨哥伦布嘉兴四平埃森天津太原孝感孟买宁波安康宣城山景城巴音郭楞常州常德广安广州开封张家口张家界徐州悉尼成都扬州抚顺攀枝花无锡昆明曲靖杭州株洲格兰特县榆林武汉汕头沈阳泉州洛杉矶洛阳济南济宁海得拉巴淮安深圳温州湖州湘潭漯河潍坊班加罗尔眉山石家庄福州绍兴罗奥尔凯埃芒廷维尤芝加哥苏州荆州莫斯科葫芦岛衡水襄阳西宁西安西雅图诺沃克贵阳赣州运城遵义邯郸郑州都柏林酒泉重庆铜仁镇江长春长沙长治随州雷德蒙德青岛香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (329) PDF downloads(41) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1352]YesterdayPV[2703]TodayIP[238]TodayPV[369]Online[15]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return